MedPath

Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Recruiting
Conditions
Lung Transplantation
Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
Registration Number
NCT03798860
Lead Sponsor
Hannover Medical School
Brief Summary

Single-arm, prospective observational study

Detailed Description

This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
75
Inclusion Criteria
  • all patients after lung transplantation with detection of donor-specific antibodies
Exclusion Criteria
  • none

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Donor-specific Antibodies Clearance6, 12, 18, 24 months

The DSA clearance is defined as absence of DSA in the Luminex test, which is performed every 6 months after treatment end.

Secondary Outcome Measures
NameTimeMethod
Graft survival1, 3, 5 years

Graft survival is defined as freedom from mortality and re-transplantation

Incidence of acute cellular and humoral rejections and chronic lung allograft dysfunction (CLAD)1, 3, 5 years

Trial Locations

Locations (1)

Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery

🇩🇪

Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath